GW501516 raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
This page was last updated on 2026-08-01 and is reviewed periodically as new material appears.
Quality assessment for cardarine samples usually combines identity, purity, and impurity testing. Nuclear magnetic resonance spectroscopy and mass spectrometry can confirm molecular structure, while high-performance liquid chromatography estimates purity. Certificates of analysis from testing laboratories may list these results, but they do not establish safety or legality. In the absence of approved manufacturing, products sold online may contain the wrong compound, variable amounts, or unlisted contaminants. Independent verification is therefore central to analytical work and to interpreting any reported biological activity.
Laboratory detection of GW501516 commonly uses liquid chromatography coupled with tandem mass spectrometry. The method can identify the parent compound or its metabolites in urine and blood after sample cleanup. Protein precipitation, solid-phase extraction, or enzymatic hydrolysis may precede analysis, depending on the matrix. Reference standards are required for accurate quantification and confirmation. Because the compound is not approved, testing often occurs in anti-doping, forensic, or research settings rather than routine clinical care. Results are reported with limits of detection and quantification.
Stability of GW501516 depends on form, temperature, light exposure, and moisture. Solid reference material is typically stored frozen or refrigerated in a desiccator and protected from light. Solutions in organic solvents such as dimethyl sulfoxide are often kept frozen in aliquots to reduce freeze-thaw cycling. Aqueous solubility is low, so aqueous stock solutions can be difficult to prepare without cosolvents. Degradation may appear as changes in chromatographic purity or mass spectral signal. Stability studies are needed to establish shelf life for any specific preparation.
A persistent misconception is that cardarine is a fat-burning drug or a safe alternative to anabolic steroids. No approved therapeutic product exists, and human safety data are limited. The tumor findings in rodents remain a central concern in scientific reviews. Products sold online may contain inaccurate labels, impurities, or different compounds entirely, which complicates any assessment of effects. Independent testing of such products has reported frequent mislabeling. For these reasons, discussions in the literature emphasize risks and unknowns rather than benefits.
Cardarine is not approved for human therapeutic use in any major jurisdiction. It appears on the World Anti-Doping Agency Prohibited List as a PPARδ agonist within the hormone and metabolic modulators category. Sports organizations test for it because it has been detected in athlete samples and seized products. Regulatory actions against marketed research chemical versions have occurred in several countries, though enforcement varies. Availability through unregulated channels complicates oversight.
Analytical laboratories typically identify cardarine and its metabolites using liquid chromatography-tandem mass spectrometry. Urine is a common matrix in anti-doping testing, while blood and tissue may be used in research settings. Detection windows depend on the assay, the sample matrix, and the compound's metabolism. Because cardarine is extensively metabolized, laboratories often target specific metabolites to improve sensitivity and confirmation. Reference standards are required for reliable quantification. Method validation includes checks for selectivity, linearity, and carryover.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white powder | Common for reference-grade material. |
| Solubility | Low in water | Dissolves in DMSO and some organic solvents. |
| Typical storage | -20 °C, desiccated | Protect from light and moisture. |
| Analytical method | LC-MS/MS | Used for trace detection in biological matrices. |
| Purity assessment | HPLC with UV detection | Often combined with NMR and mass spectrometry. |
Human trials of GW501516 were small and short in duration. They examined lipid levels, glucose handling, and other metabolic markers, but the programs were halted after the animal cancer findings. No approved therapeutic product exists, and published human data are insufficient for establishing long-term safety. Reports of use for athletic performance come mainly from non-clinical settings and cannot be verified through controlled trials. Independent testing of products sold as cardarine has found inconsistent purity and labeling.
Laboratory studies indicate that GW501516 activates PPARδ, a nuclear receptor involved in fatty acid oxidation and energy metabolism. In rodent experiments, treated animals often showed increased endurance and reduced fat mass. These effects were observed under controlled conditions and do not establish safe or effective use in humans. The exact dose-response relationship in humans remains poorly characterized. Species differences in metabolism can affect how results translate across animals and people.
Safety concerns emerged from long-term animal studies. In rodents given the compound for extended periods, researchers found an increased incidence of certain cancers, including liver and bladder tumors. These findings contributed to the discontinuation of clinical development. Whether similar risks apply to short-term or low-level exposure in humans is not established, and controlled human safety data are limited. The relevance of high-dose rodent carcinogenicity findings to human use remains a subject of debate.
Because cardarine is not an approved medicine, no pharmacopeial monograph defines its identity, purity, or storage requirements. Laboratories typically rely on in-house methods and reference standards when testing materials labeled as GW501516. Certificates of analysis may report purity and identity for a specific batch, but their scope varies and they do not guarantee safety or legal status. Independent verification can include high-performance liquid chromatography, mass spectrometry, nuclear magnetic resonance, and elemental analysis. The distinction between research chemical labeling and human use is significant because quality standards and oversight differ.
Cardarine can be detected in biological samples and product materials using liquid chromatography coupled to tandem mass spectrometry (LC-MS/MS). The method separates compounds by chromatography and identifies them by mass-to-charge transitions, allowing low-level detection in urine or blood. Sample preparation often involves enzymatic hydrolysis, solid-phase extraction, or protein precipitation. Certified reference materials and isotope-labeled internal standards improve quantification. Detection windows depend on metabolism, matrix, and assay sensitivity, so no single universal window applies.
Regulatory treatment of cardarine differs by context and jurisdiction. In competitive sport, the World Anti-Doping Agency lists PPARδ agonists, including GW501516, as prohibited at all times. Outside sport, it lacks approval as a prescription medicine in major drug markets, and products sold for human consumption may be treated as unapproved drugs. Some countries also restrict importation or sale through general consumer protection and medicines laws. These classifications affect availability, testing, and legal risk without establishing therapeutic value.
Clinical development stopped after rodent studies showed tumors at multiple sites. Whether those findings predict human cancer risk remains an open question, but they led sponsors to discontinue programs. Human safety data are limited to small, short-term studies that were not designed to assess cancer risk. Reported effects in those studies included changes in blood lipids, but the evidence is insufficient for medical use. Long-term consequences of nonmedical use are not well characterized. Questions about dose, duration, and individual susceptibility remain unresolved.
Cardarine is a common name for GW501516, an investigational compound developed in the 1990s for metabolic conditions. It acts as an agonist at peroxisome proliferator-activated receptor delta, a nuclear receptor involved in lipid and energy metabolism. The compound is frequently mislabeled as a selective androgen receptor modulator, or SARM, but its molecular target is different. GW501516 reached early clinical testing before development was discontinued. It has no approved therapeutic use in any country. The name cardarine is not a formal international nonproprietary name.
Regulatory treatment varies, but cardarine is not approved as a medicine. Sports authorities list GW501516 as a prohibited substance, and it is banned at all times under the World Anti-Doping Agency code. Many countries restrict sales for human consumption, while online vendors market it as a research chemical. Such products may lack purity data, and their actual contents can differ from the label. Purchasing or possessing cardarine may carry legal consequences depending on jurisdiction. The compound is not a dietary supplement ingredient in regulated markets.
=== Film and other TV appearances === In addition to the game shows for which he became famous, Barker also hosted the annual/biennial Pillsbury Bake-Off (the bake-off occurred every two years starting in 1976). In 1978, he was the first host to have a male category champ. From 1969-1988 he also co-hosted CBS's coverage of the Rose Parade from Pasadena, California. On September 7, 2009, Barker was a special guest host for WWE Raw (called "The Price is Raw") in Rosemont, Illinois. Aired during a period when nearly every episode of the weekly wrestling show featured a celebrity guest host, with mixed results, Barker's appearance has been ranked the best of nearly 80 hosts. Barker also agreed to be a rotating guest co-host on The Huckabee Show, a daily TV talk show hosted by Mike Huckabee. Barker first appeared on the show on July 29, 2010. Barker's fame from his television hosting roles also saw him become a popular guest on other shows, including as a semi-regular panelist on the game shows Tattletales (1975–1976, with wife Dorothy Jo) and Match Game (1973–1980). Barker sat in Richard Dawson's former place during the first week after Dawson permanently left Match Game. Barker also made appearances on various talk shows such as: Dinah!, Larry King Live, The Arsenio Hall Show, Crook & Chase, Donny & Marie, The Rosie O'Donnell Show, The Ellen DeGeneres Show, The Wayne Brady Show, the Late Show with David Letterman, and The Late Late Show with Craig Ferguson.
Lysyl hydroxylases (or procollagen-lysine 5-dioxygenases) are alpha-ketoglutarate-dependent hydroxylases enzymes that catalyze the hydroxylation of lysine to hydroxylysine. Lysyl hydroxylases require iron and vitamin C as cofactors for their oxidation activity. It takes place (as a post-translational modification) following collagen synthesis in the cisternae (lumen) of the rough endoplasmic reticulum (ER). There are three lysyl hydroxylases (LH1-3) encoded in the human genome, namely: PLOD1, PLOD2 and PLOD3. From PLOD2 two splice variant can be expressed (LH2a and LH2b), where LH2b differs from LH2a by incorporating the small exon 13A. LH1 and LH3 hydroxylate lysyl residues in the collagen triple helix, whereas LH2b hydroxylates lysyl residues in the telopeptides of collagen. In addition to its hydroxylation activity, LH3 has glucosylation activity that produces disaccharide (Glc-Gal) attached to collagen hydroxylysines. Collagen lysyl hydroxylation is the first step in collagen pyridinoline cross-linking, that is necessary for the stabilization of collagen.
=== Primary intention === Primary intention is the healing of a clean wound without tissue loss. In this process, wound edges are brought together, so that they are adjacent to each other (re-approximated). Wound closure is performed with sutures (stitches), staples, or adhesive tape or glue. Primary intention can only be implemented when the wound is precise and there is minimal disruption to the local tissue and the epithelial basement membrane, e.g. surgical incisions. This process is faster than healing by secondary intention. There is also less scarring associated with primary intention, as there are no large tissue losses to be filled with granulation tissue, though some granulation tissue will form.
Both of these reported discoveries were shown to be erroneous because the spectrum line that "corresponded" to element 61 was identical to that of didymium; the lines thought to belong to element 61 turned out to belong to a few impurities (barium, chromium, and platinum). In 1934, Josef Mattauch finally formulated the isobar rule. One of the indirect consequences of this rule was that element 61 was unable to form stable isotopes. From 1938, a nuclear experiment was conducted by H. B. Law et al. at the Ohio State University. Nuclides were produced in 1941 which were not radioisotopes of neodymium or samarium, and the name "cyclonium" was proposed, but there was a lack of chemical proof that element 61 was produced and the discovery was not largely recognized.
An IDF spokesperson stated the attack was "an official declaration of war by Hezbollah" and vowed to "neutralize" the threat. Israel struck southern Lebanon, Beirut, and the Beqaa Valley, with the IDF saying it had killed the head of Hezbollah's intelligence Hussein Makled and Adham Adnan al-Othman, the head of Palestinian Islamic Jihad's armed wing, the Al-Quds Brigades. The Royal Air Force station at Akrotiri, Cyprus, was targeted by a drone strike causing damage to a runway. Another strike on Cyprus led to Greece announcing that it would deploy frigates and F-16s to defend Cyprus from strikes by Iran. The pro-Iran militant group Iraqi Guardians of Blood Brigades claimed responsibility for attacks on the US Victory Base near Baghdad International Airport and Erbil in the Kurdistan Region of Iraq. The Islamic Resistance in Iraq claimed responsibility for 23 drone strikes on US assets in Erbil.
Sources: en.wikipedia.org
Beginning in 1939, Drew traveled every year to Tuskegee, Alabama, to attend the annual free clinic at the John A. Andrew Memorial Hospital. For the 1950 Tuskegee clinic, Drew drove along with three other black physicians. Drew was driving around 8 a.m. on April 1. Still fatigued from spending the night before in the operating theater, he lost control of the vehicle. After careening into a field, the car somersaulted three times. The three other physicians sustained minor injuries. Drew was trapped with severe wounds; his foot was wedged beneath the brake pedal. When reached by emergency technicians, he was in shock and barely alive due to severe leg injuries. Drew was taken to Alamance General Hospital in Burlington, North Carolina. He was pronounced dead a half hour after he first received medical attention. Drew's funeral was held on April 5, 1950, at the Nineteenth Street Baptist Church in Washington, D.C. Despite a popular myth to the contrary, once repeated on an episode ("Dear Dad... Three") of the TV series M*A*S*H and in the novels Carrion Comfort, The 480, and The Human Stain, Drew's death was not the result of his having been refused hospital access because of his race. According to John Ford, one of the passengers in Drew's car, Drew's injuries were so severe that virtually nothing could have been done to save him. Ford added that a blood transfusion might have actually killed Drew sooner.
A tetrameric protein is a protein with a quaternary structure of four subunits (tetrameric). Homotetramers have four identical subunits (such as glutathione S-transferase), and heterotetramers are complexes of different subunits. A tetramer can be assembled as dimer of dimers with two homodimer subunits (such as sorbitol dehydrogenase), or two heterodimer subunits (such as hemoglobin).
=== Death and legacy === Pauling died of prostate cancer on August 19, 1994, at 19:20 at home in Big Sur, California. He was 93 years old. A grave marker for Pauling was placed in Oswego Pioneer Cemetery in Lake Oswego, Oregon by his sister Pauline, but Pauling's ashes, along with those of his wife, were not buried there until 2005. Pauling's discoveries led to decisive contributions in a diverse array of areas including around 350 publications in the fields of quantum mechanics, inorganic chemistry, organic chemistry, protein structure, molecular biology, and medicine. His work on chemical bonding marks him as one of the founders of modern quantum chemistry. The Nature of the Chemical Bond was the standard work for many years, and concepts like hybridization and electronegativity remain part of standard chemistry textbooks. While his valence bond approach fell short of accounting quantitatively for some of the characteristics of molecules, such as the color of organometallic complexes, and would later be eclipsed by the molecular orbital theory of Robert Mulliken, valence bond theory still competes, in its modern form, with molecular orbital theory and density functional theory (DFT) as a way of describing chemical phenomena. Pauling's work on crystal structure contributed significantly to the prediction and elucidation of the structures of complex minerals and compounds. His discovery of the alpha helix and beta sheet is a fundamental foundation for the study of protein structure. Francis Crick acknowledged Pauling as the "father of molecular biology".
The giant Pacific octopus (Enteroctopus dofleini) is often cited as the largest octopus species. Adults usually weigh 10–50 kg (22–110 lb), with an arm span of up to 4.8 m (16 ft). The largest specimen of this species to be scientifically documented reached a live mass of 71 kg (157 lb). Much larger sizes have been claimed: one specimen was recorded as 600 lb (270 kg) with an arm span of 32 ft (9.8 m). A carcass of the seven-arm octopus, Haliphron atlanticus, weighed 61 kg (134 lb) and was estimated to have had a live mass of 75 kg (165 lb). The smallest species is Octopus wolfi, which is around 2.5 cm (1 in) and weighs less than 1 g (0.035 oz).
Lercanidipine (INN) is an antihypertensive (blood pressure lowering) drug. It belongs to the dihydropyridine class of calcium channel blockers, which work by relaxing and opening the blood vessels allowing the blood to circulate more freely around the body. This lowers the blood pressure and allows the heart to work more efficiently. This drug (trade name Zanidip, among others) acts more slowly than older dihydropyridines. It probably has fewer adverse effects, but a comparatively high potential for drug interactions. It was patented in 1984 and first approved for medical use in 1997. The FDA refused to approve the drug, and lercanidipine is not marketed in the United States.
Sources: en.wikipedia.org
LC-MS/MS is common, often after sample cleanup. The assay targets GW501516 or its metabolites.
Reference material is usually kept cold, dry, and protected from light. Frozen aliquots reduce repeated freeze-thaw cycles.
No approved pharmaceutical product exists, so manufacturing and quality controls are not standardized. Products may contain different compounds or impurities.
No. Cardarine has not received approval for human therapeutic use in major jurisdictions. It remains an investigational compound.